Bank of New York Mellon Corp Takes $1.63 Million Position in MiMedx Group, Inc $MDXG

Key Points

• Bank of New York Mellon acquired 423,055 MiMedx Group shares worth approximately $1.63 million, giving it a 0.29% stake. Institutional investors collectively own 79.15% of the company.
• Analyst sentiment is broadly positive: six analysts rate MDXG a Buy and one rates it Sell, resulting in a “Moderate Buy” consensus and an average price target of $8.57.
• MiMedx shares opened at $4.67, up 2.2%, while the company reported quarterly revenue of $64.36 million and adjusted to analysts’ expected loss of $0.05 per share.

Bank of New York Mellon Corp purchased a new stake in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 423,055 shares of the company's stock, valued at approximately $1,629,000. Bank of New York Mellon Corp owned 0.29% of MiMedx Group as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada grew its position in MiMedx Group by 1.4% during the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company's stock worth $7,466,000 after purchasing an additional 13,629 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company's stock valued at $109,000 after purchasing an additional 4,296 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of MiMedx Group in the first quarter worth $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company's stock valued at $559,000 after buying an additional 4,049 shares in the last quarter. Finally, Millennium Management LLC raised its position in MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company's stock valued at $9,355,000 after buying an additional 596,016 shares during the period. Hedge funds and other institutional investors own 79.15% of the company's stock.

Analysts Set New Price Targets

MDXG has been the subject of a number of research reports. Craig Hallum raised their price objective on MiMedx Group from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Wall Street Zen raised shares of MiMedx Group from a "sell" rating to a "hold" rating in a research report on Saturday, August 29th. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a research report on Monday, August 17th. Finally, Weiss Ratings upgraded shares of MiMedx Group from a "sell (d)" rating to a "sell (d+)" rating in a research report on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.57.

MiMedx Group Trading Up 2.2%

Shares of NASDAQ MDXG opened at $4.67 on Wednesday. The stock has a market cap of $680.70 million, a price-to-earnings ratio of 116.78 and a beta of 1.43. The business has a 50 day simple moving average of $4.29 and a 200 day simple moving average of $4.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33. MiMedx Group, Inc has a 52 week low of $3.03 and a 52 week high of $7.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The company had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. On average, research analysts predict that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.